CW 002

CW 002 (also written as CW002) is a novel non-depolarizing neuromuscular blocking drug that belongs to the benzylisoquinolinium family. It's a fumarate diester compound with a molecular structure similar to gantacurium, differing only by lacking a chlorine at the fumarate double bond and being symmetrical. ## Pharmacology and Mechanism of Action CW002 works by blocking neuromuscular transmission, preventing muscles from contracting. It's designed to have an intermediate duration of action, with spontaneous recovery to a train-of-four ratio ≥95% occurring in about 30 minutes. The drug is inactivated through two primary mechanisms: 1. L-cysteine adduction (which is pH dependent) 2. Alkaline hydrolysis (with a half-life of 11.4 minutes) These degradation processes result in molecular fragments (NB 1043-10) that have only 0.01-0.001 times the neuromuscular potency of the parent compound[1]. ## Pharmacokinetics and Efficacy In animal studies, CW002 demonstrated an ED95 (effective dose for 95% effect) of 0.01-0.04 mg/kg. Its onset of action is shorter than cisatracurium but longer than rocuronium. In Rhesus monkeys, CW002 showed 2.5 times the potency of rocuronium[1]. Pharmacokinetic modeling indicates CW002 has linear pharmacokinetics with very low interindividual variability in clearance (10.8%). At 3× ED95, it's predicted to have a rapid onset with an intermediate duration of action[2]. ## Clinical Development CW002 was initially developed by Cornell University and has been studied in clinical trials. A study at Weill Medical College of Cornell University was initiated in May 2011 to test the safety and efficacy of CW002 in healthy adult volunteers[2]. The drug has not yet been approved by the FDA and appears to have a discontinued development status[2]. ## Advantages and Potential Applications CW002 was designed to interact more slowly with endogenous L-cysteine than gantacurium, resulting in an intermediate duration of action. Unlike neostigmine (which can only antagonize moderate-to-light levels of blockade), reversal from every level of CW002-induced neuromuscular block can potentially be facilitated through L-cysteine administration[1]. If proven safe and effective, CW002 could be useful in surgical procedures where a neuromuscular blocking agent with intermediate duration is desired, potentially improving anesthetic care[2].